Gemalto Launches Virtualized Network Encryption Platform to Help Customers Address Evolving Data Security Needs
Gemalto, the world leader in digital security, today announced the launch of a new virtualized network encryption platform, SafeNet Virtual Encryptor CV1000 as part of its continued investment to address the rapidly changing data security needs of organizations worldwide.
(Gemalto will host a webinar entitled, “Network Encryption at the Flip of a Switch: Implementing Virtualized Network Encryption to Secure SD-WANs”, on June 21st at 3 p.m. Central European Time. Click here to register.)
Today, enterprises and service providers are increasingly using network functions virtualization (NFV) and software-defined networking (SDN) technologies to design, deploy and manage their networks and cloud-based services. These software-based technologies give organizations cost and operational benefits because they move network functions from dedicated network encryption hardware appliances to virtual servers. However, these technologies can also present additional security challenges for protecting sensitive data that runs across these networks because of their virtualized architecture.
Leveraging the proven security and performance of the hardware-based SafeNet High Speed Encryptor family, the SafeNet Virtual Encryptor CV1000 is a hardened virtual security appliance designed to secure data in motion across both software-defined wide area networks (SD-WAN) and traditional networks. Developed by Gemalto’s high speed encryption partner, Senetas (ASX:SEN), the SafeNet Virtual Encryptor CV1000 can encrypt data in motion at data-rates up to 5 Gbps.
“More and more organizations are embracing the advantages of virtualized networks to deliver cost-effective scalability, flexibility and network management to the network edge. Consequently, network services require trusted virtualized encryption for optimum data security,” said Todd Moore, senior vice president of Encryption Products at Gemalto. “Gemalto’s launch of a virtualized network encryption platform redefines network data security by providing the crypto-agility required to ensure sensitive data and transmissions remain secure, regardless of network design.”
Transforming the network encryption market, SafeNet High Speed Encryptors are the first to offer Transport Independent Mode, which enables organizations to encrypt data across mixed high speed WAN links (Layers 2, 3 and 4). Organizations can now be assured that they are getting the best performance and secure encryption, regardless of the network layer. This feature is currently available for the SafeNet Virtual Encryptor CV1000, and will be available for the hardware-based SafeNet High Speed Encryptors later this year.
“As organizations increasingly embrace cloud-based applications and their use of multiple network types from Ethernet to MPLS, Senetas and Gemalto are ahead of the curve in providing seamless concurrent multi-layer network traffic encryption to ensure the best in network security and performance available today,” said Andrew Wilson, CEO of Senetas.
Key Features and Benefits of the SafeNet Virtual Encryptor CV1000 include:
- Virtualized Network Functionality reduces dependence on dedicated network encryption hardware appliances for both enterprises and network operators.
- Reduced Cost of Ownership makes the SafeNet Virtual Encryptor CV1000 up to 10 times more affordable than hardware-based appliances.
- Rapid Deployment and Scalability enables organizations to spin up a virtual machine to protect data across the network rather than having to physically deploy hardware at each end point.
- Crypto-Agile Encryption Across All Network Layers with Transport Independent Mode, providing the ability to encrypt traffic across Layers 2, 3 and 4 with optimized performance and robust encryption, including support for custom algorithms.
- Combined Encryption Key Management option, integrates with SafeNet KeySecure for enhanced key lifecycle management.
- Product Brief: SafeNet Virtual Encryptor CV1000
- Video: SafeNet High Speed Encryptors
- Webinar: Gemalto will host a webinar entitled, “Network Encryption at the Flip of a Switch: Implementing Virtualized Network Encryption to Secure SD-WANs“, on June 21st at 3pm Central European Time. Click here to register.
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security, with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
Tauri Cox, +1 512 257 3916
Europe Middle East & Africa
Sophie Dombres, +33 4 42 36 57 38
Jaslin Huang, +65 6317 3005
Enriqueta Sedano, +52 5521221422
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors17.6.2019 16:00:00 CEST | Pressemelding
Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor. “We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes fo
MagicStay Raises €3 Million to Accelerate Its International Development17.6.2019 15:58:00 CEST | Pressemelding
The apartment rental platform dedicated to business travelers, MagicStay.com , announces its full integration into the main business travel booking tools and a €3 million A-series to pursue its development, bringing the amounts raised to more than €8 million since its launch in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005644/en/ William Lecerf and Valéry Linyer, co-founders of MagicStay (Photo: MagicStay) "This fundraising will allow us to recruit talent to accelerate our growth. We want to sign a quarter of the major French companies and approach one million homes before the end of the year, thanks to the exclusive technologies we now have at our disposal", says Valéry Linÿer, CEO and co-founder, who adds: "We have four main advantages over our competitors: we meet the challenges of duty of care, we are able to customize our tool to meet the constraints of each large company for short and long stays, we ha
EURid Shows a 94% Reduction of Its Footprint since 201217.6.2019 15:32:00 CEST | Pressemelding
EURid, the not-for-profit organisation that operates the .eu and .ею top-level domains, is the first European TLD registry that registered for the EU Eco-Management and Audit Scheme (EMAS) from 2011. Since then, EURid has regularly assessed the environmental impact of its activities and monitored the compliance of its policies and procedures. As over the past four years, in Q2 2019 EURid was audited for the CO2 emissions of the previous year, resulting in an overall footprint of 135 tons CO2eq, which shows a 94% reduction since 2012. “We have achieved carbon neutrality via several actions and the compensation of the audited emissions. We were and are still among the first in our sector to report on our commitment to protect the environment”, commented CEO Marc Van Wesemael. Through EMAS, EURid has had the opportunity to support a multitude of global sustainability initiatives, like the Ugandan Borehole Project, Ecomapuà Project in the Amazon, the Dak Rung Hydropower Project in Vietnam,
Animation, Sound & Vibration – How Visa is Reinforcing Consumer Trust in a Changing Payments World17.6.2019 15:00:00 CEST | Pressemelding
Visa (NYSE: V) today announced global adoption of its sensory branding suite in 25 countries via more than a dozen new partnerships. The suite is comprised of sound, animation and haptic brand cues that occur with a Visa payment transaction. In a digital world increasingly filled with voice-commands, networked appliances and unattended retail environments, Visa’s sensory branding cues offer new ways to enhance the customer experience and convey the trust and security that the Visa brand represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005240/en/ Visa was the first major payment brand to introduce multi-sensory branding, which included animation, sound and haptic vibration expressions of its brand. After an extensive creation and selection process that involved focus groups and elimination rounds, Visa landed on a single ‘energetic’ and ‘optimistic’ sound, and complementary animation and haptic vibration. Sinc
Study from Project Management Institute Identifies Six AI Technologies Impacting Project Professionals17.6.2019 14:40:00 CEST | Pressemelding
Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance. The report provides an in-depth look at how artificial intelligence (AI) is impacting organizations and the project management profession. Findings reveal that AI disruption is happening and at a large scale: 81 percent of respondents report their organization is being impacted by AI technologies; 37 percent say adopting AI technologies is a high priority for their organization; and project professionals say they expect the proportion of the projects they manage using AI will jump from 23 to 37 percent over the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005558/en/ These insights from a survey of 551 project management practitioners globally show that the presence of AI technologies will continue to grow, requiring shifts in how projects are m
RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration17.6.2019 13:15:00 CEST | Pressemelding
RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD). SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy. Through the 56-Day exit visit, excluding one uncompleted case in the last cohort, single dose of RBM-007 demonstrated no dose-limiting toxicities, no systemic or ocular serious adverse events. One subject in Cohort 3 showed anterior inflammation, which was resolved after one day of topical prednisolone treatment. Rescue treatment with anti-VEGF therapy was ava